D uring the past several years, an increasing number of children and adolescents have been treated with antipsychotics. A substantial proportion of these young people are diagnosed with ADHD, CD, or ODD. 1 Safety concerns, especially weight gain, have focused attention on the risk-benefit trade-offs of evolving antipsychotic prescribing standards and practices 2 and have increased interest in evaluating the efficacy of antipsychotics for DBDs.
In this issue of The Canadian Journal of Psychiatry, Dr Scott B Patten and colleagues 3 provide a timely review of trends in antipsychotic use among young people and Dr Tamara Pringsheim and Dr Daniel Gorman 4 assess clinical trials of SGAs for DBDs. Taken together, these 2 articles inform critical ongoing clinical, policy, and academic discussions over the appropriate role of SGAs in child and adolescent mental health care.
We learn from Dr Patten and colleagues 3 that antipsychotic use in young people has increased in Canada, the United States, the United Kingdom, Italy, and the Netherlands, with considerably lower absolute use rates in Europe than in North America. Adults in Europe and North America are also increasingly receiving antipsychotics. 5 In youth, uniformly higher rates of antipsychotic treatment among males than females, with peak use in late childhood and early adolescence, are consistent with the clinical epidemiology of the disruptive behavioural disorders. 6 Although more detailed practice-based research is necessary to determine the most common target symptoms of child and adolescent antipsychotic treatment, the diagnostic patterns suggest that controlling problematic aggressive behaviours is a common clinical objective.
Large cross-national differences in antipsychotics are unlikely to be explained in full by variations in the underlying prevalence of child and adolescent disorders in clinical care. Instead, Canadian and US physicians appear to be more receptive than their European colleagues to prescribing antipsychotics to young people. Greater SGA use in the United States than in Germany or the Netherlands has also been described in the treatment of child-onset bipolar disorder. 7 To help ensure that North American physicians strike an appropriate balance, now may be a good time to reassess the efficacy of nonpharmacological interventions for aggressive behaviours in youth, such as parent management training, cognitive problem solving skills training, multisystemic therapy, 8 and other interventions that incorporate cognitive-behavioural therapy strategies. 9 Antipsychotics have traditionally been the province of psychiatric practice. Dr Patten and colleagues 3 make the point that primary care physicians play a significant role in antipsychotic treatment of children and adolescents. While psychiatrists account for most (62%) antipsychotic prescriptions for Canadian youth, family physicians (17%) and general practitioners (17%) also make nontrivial contributions. 10 Early adopters of medical interventions are often specialists rather than primary care physicians. 11 For stimulants-the most well-established psychotropic treatment of youth, Canadian psychiatrists account for only 17% of prescriptions. 10 Over time, it will be important to track the diffusion of antipsychotic treatment of children and adolescents from psychiatrists to primary care physicians. If pediatricians and family practitioners assume a more prominent role in prescribing antipsychotics to children and adolescents, increased consultations with psychiatrists will need to ensure appropriate patient selection and medication dosing.
The review by Dr Pringsheim and Dr Gorman 4 establishes that substantial progress has been made in defining the efficacy of risperidone in children with aggressive behaviour, especially in the context of CD or ODD. In these patient populations, risperidone delivers significant reductions in conduct problems and global illness severity. Earlier research on residential youth with subaverage intelligence has been extended to higher-functioning patients. Some evidence further supports maintenance risperidone treatment for youth with early positive responses. 12 In Europe, but not in Canada or the United States, risperidone has been approved for aggression in the context of CD. 13 Much of the concern over off-label antipsychotic treatment centres on drug safety. Children and adolescents appear to be particularly sensitive to the adverse metabolic effects of SGAs. Compared with adults, young people may be more vulnerable to antipsychotic-induced weight gain 14 and perhaps even to antipsychotic-associated diabetes. 15 To evaluate these risks, physicians need access to reliable information concerning metabolic effects associated with drug dosages that are routinely used in practice. In the clinical literature on risperidone for CD, dosages generally hover around 1 mg daily. This is lower than the mean risperidone dosages in child and adolescent schizophrenia that approach 3 mg daily, and are associated with significant short-term weight gain. 16 In one study of first-time antipsychotic use by children and adolescents, risperidone dosages above 1.5 mg daily, compared with lower dosages, resulted in significantly greater increases in weight and waist circumference. 17 Antipsychotics are often prescribed to young people with ADHD. In Canada, ADHD accounts for about 17% of youth antipsychotic use. 10 In the Medicaid program in the United States, the corresponding estimates range from 29% 18 to 61%. 1 It is unknown whether the large group of children and adolescents with ADHD and intermittent aggressive behaviours derive the same benefits from SGAs that have been observed with more severe DBDs. Although one pilot study failed to demonstrate benefit in youth with ADHD and aggressive behaviour, 19 more work, with larger samples, is clearly needed.
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Rapidly increasing antipsychotic treatment of children and adolescents stands in sharp contrast with the slow and steady accumulation of reliable efficacy information from controlled trials in this age group. At present, policy makers who seek to honour patient and parent preferences and respect physician autonomy, while maintaining quality standards and controlling costs, must grapple with widespread off-label antipsychotic treatment of children and adolescents. Concurrently, front-line child and adolescent psychiatrists, as well as primary care physicians, confront the need to make management decisions in clinical situations for which there is little information from clinical trials to guide their selection of treatments. These realworld tensions highlight the need for public investment in clinical trials of antipsychotics for children and adolescents with ADHD and related disorders to help better define the limits of safe and effective practice.
